UBS lifts its Genmab target by 58 per cent as all twelve houses go up
This Consensus Analysis of Genmab includes the analyst houses that published a target within 90 days prior to 17 November 2026.
Twelve houses are included and all twelve raised their target. Ten did so before the Q3 report of 5 November, and two have published since.
The median target of 4,450 DKK is 27.1 per cent above the close of 3,502.00 DKK on 17 November 2026, and the mean of 4,204 DKK is 20.1 per cent above it.
Snapshot as of 17 November 2026
All public targets
Fifteen houses have published targets or ratings for Genmab in the last twelve months. Out of these, twelve presented an updated target within the time window for this analysis, spanning from 90 days prior to 17 November. These twelve are the basis for the aggregates in this Consensus Analysis.
Sydbank lowered its rating to Hold on 29 October without a published target. Handelsbanken and Bernstein last published in March and February. These three sit below the divider and are left out of the aggregates.
BNP Paribas, Kempen and Rothschild & Co Redburn also cover the share, but are left out because their latest target could not be matched to a dated public notice.
| House | Previous | Target | Rec. | Last |
|---|---|---|---|---|
| UBS [6] | 3,100 | ▲4,900 | Buy | 16 Nov |
| SEB [7] pre-report | 3,175 | ▲4,600 | Buy | 29 Oct |
| TD Cowen [8] pre-report | 3,435 | ▲4,526 | Buy | 29 Oct |
| Barclays [9] pre-report | 3,400 | ▲4,500 | Overweight | 29 Oct |
| Goldman Sachs [10] | 4,450 | ▲4,500 | Buy | 6 Nov |
| Nordea [11] pre-report | 3,200 | ▲4,500 | Buy | 29 Oct |
| Bank of America [12] pre-report | 4,200 | ▲4,400 | Buy | 2 Nov |
| DNB Carnegie [13] pre-report | 3,100 | ▲4,100 | Hold | 29 Oct |
| Deutsche Bank [14] pre-report | 3,500 | ▲4,000 | Buy | 29 Oct |
| Jyske Bank [15,17] pre-report | 2,925 | ▲3,725 | Sell | 29 Oct |
| J.P. Morgan [16,17] pre-report | 2,050 | ▲3,500 | Overweight | 26 Oct |
| Jefferies [18] pre-report | 2,900 | ▲3,200 | Buy | 26 Oct |
| Sydbank [19] | – | no target | Hold | 29 Oct |
| Handelsbanken [20] | 2,200 | ▲2,220 | Buy | 3 Mar |
| Bernstein [21] | 1,015 | ▲1,400 | Underperform | 23 Feb |
pre-report Target set before the Q3 report of 5 November 2026. With only two targets published since the report, the aggregates use the 90 days to 17 November 2026 and the row is included.
Barclays and J.P. Morgan published Overweight, which normalises to Buy. Bernstein published Underperform, which normalises to Sell. Targets published only on the US-listed ADR in dollars are not carried.
Scroll the table sideways to see every column.
Where the panel sits
Of the twelve included targets, ten sit above the close of 3,502.00 DKK on 17 November 2026 and two sit below it.
Seven of the twelve lie between 4,400 and 4,900 DKK, and the full range runs from 3,200 to 4,900 DKK.
Buy · Hold · Sell
Ten of the twelve included analyst houses rate the share Buy. DNB Carnegie rates it Hold and Jyske Bank Sell.
The percentages are rounded and sum to 99 per cent.
Dated events behind the panel
- 5 Oct 2026Epcoritamab with R-CHOP improves progression-free survival in phase IIIGenmab and AbbVie reported that the EPCORE DLBCL-2 trial of epcoritamab with R-CHOP showed a statistically significant improvement in progression-free survival in newly diagnosed diffuse large B-cell lymphoma. [2]
- 23 Oct 2026Rina-S phase III RAINFOL-02 meets progression-free and overall survivalIn platinum-resistant ovarian cancer, Rina-S cut the risk of disease progression or death by 71 per cent against investigator's choice chemotherapy in the intent-to-treat population (HR 0.29). The trial also met its key secondary endpoint of overall survival. [3]
- 28 Oct 2026Petosemtamab phase III LiGeR-HN1 meets both primary endpointsAt the first interim analysis, petosemtamab with pembrolizumab halved the risk of death against pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic head and neck cancer (HR 0.50) and improved the objective response rate. [4]
- 5 Nov 2026Q3 report: revenue up 22 per cent, guidance keptRevenue for the first nine months was 3,238 million dollars against 2,662 million a year earlier. Diluted net profit per share was 11.23 dollars against 14.90 dollars. The 2026 guidance published on 6 August was maintained. [1]
Three takeaways from the panel
Jefferies at 3,200 DKK and J.P. Morgan at 3,500 DKK published on 26 October, after the RAINFOL-02 results and two days before LiGeR-HN1.
The other ten included targets were set from 29 October onward and lie between 3,725 and 4,900 DKK. Their mean is 4,375 DKK, 24.9 per cent above the close.
Jyske Bank lowered Genmab to Sell on 29 October with a target of 3,725 DKK, 6.4 per cent above the close. Its previous target was 2,925 DKK. [17]
DNB Carnegie lowered Genmab to Hold the same day with a target of 4,100 DKK, up from 3,100 DKK and 17.1 per cent above the close.
Goldman Sachs added 50 DKK to its target on 6 November, a rise of 1.1 per cent.
UBS raised its target by 58.1 per cent on 16 November, to 4,900 DKK from 3,100 DKK. Its previous target dated from 14 October, before the RAINFOL-02 and LiGeR-HN1 readouts. [22]
Numbered sources
- Genmab interim report for the nine months ended 30 September 2026, company announcement no. 45
- Genmab and AbbVie announce epcoritamab in combination with R-CHOP demonstrates statistically significant improvement in progression-free survival in patients with newly diagnosed DLBCL
- Genmab announces rinatabart sesutecan (Rina-S) demonstrates statistically significant improvement in progression-free survival and overall survival in patients with platinum-resistant ovarian cancer
- Genmab announces statistically significant, clinically meaningful improvement in overall survival and objective response with petosemtamab combination at first interim analysis in first-line R/M patients with PD-L1+ head and neck cancer
- Genmab closing price of 3,502.00 DKK on Nasdaq Copenhagen
- UBS raises its target price for Genmab to 4,900 DKK (3,100), reiterates Buy
- SEB raises its target price for Genmab to 4,600 DKK (3,175), reiterates Buy
- TD Cowen raises its target price for Genmab to 4,526 DKK (3,435), reiterates Buy
- Barclays raises its target price for Genmab to 4,500 DKK (3,400), reiterates Overweight
- Goldman Sachs raises its target price for Genmab to 4,500 DKK (4,450), reiterates Buy
- Nordea raises its target price for Genmab to 4,500 DKK (3,200), reiterates Buy
- Bank of America raises its target price for Genmab to 4,400 DKK (4,200), reiterates Buy
- DNB Carnegie lowers Genmab to Hold (Buy), target price 4,100 DKK (3,100)
- Deutsche Bank raises its target price for Genmab to 4,000 DKK (3,500), reiterates Buy
- Jyske Bank lowers Genmab to Sell (Hold), target price 3,725 DKK
- J.P. Morgan raises Genmab to Overweight (Neutral), target price 3,500 DKK
- Target price raises after strong study data for Rina-S: J.P. Morgan 3,500 DKK (2,050), Jyske Bank 2,925 DKK (2,350) and other houses
- Jefferies raises its target price for Genmab to 3,200 DKK (2,900), reiterates Buy
- Sydbank lowers Genmab to Hold (Buy)
- Handelsbanken raises its target price for Genmab to 2,220 DKK (2,200), reiterates Buy
- Bernstein raises its target price for Genmab to 1,400 DKK (1,015), reiterates Underperform
- UBS raises its target price for Genmab to 3,100 DKK (2,700), reiterates Buy
How the report was compiled
Selection. Each row in the panel is taken from its own dated notice, listed individually in the references. A house whose latest target could not be matched to a dated notice is left out rather than carried on an unverified figure. Sell-side houses only; independent research sold to end investors is outside the panel. Targets published only on the US-listed ADR in dollars are not carried. The aggregates normally use targets published after the issuer's most recent interim report. Two houses published after the Q3 report of 5 November 2026, so the aggregates use every target set in the 90 days to 17 November 2026: twelve houses, ten of them marked pre-report. Sydbank, which published a rating without a target, and Handelsbanken and Bernstein, whose latest targets are older than 90 days, are listed below the divider and are not in the aggregates.
Price and valuation basis. Consensus is referenced against the closing price of 3,502.00 DKK on Nasdaq Copenhagen on 17 November 2026. [5] Market capitalisation uses 61,494,537 shares: the 62,405,855 shares the Q3 report gives for 30 September 2026, less the 911,318 treasury shares Genmab held on that date. [1] Genmab reports in US dollars, so the price-earnings ratio converts the close at 6.2 DKK per dollar, the rate the company's 2026 guidance assumes, giving 564.84 dollars. That is a planning assumption and not a market rate on the snapshot date, and it is the same basis as the August 2026 report. The earnings are trailing twelve months of diluted net profit per share: 15.37 dollars for 2025, less 14.90 for the first nine months of 2025, plus 11.23 for the first nine months of 2026, or 11.70 dollars. [1] At 6.0 DKK per dollar the ratio would be 49.9x, and at 6.4 it would be 46.8x.
Ratings. Buy, Overweight and Outperform normalise to Buy; Hold, Neutral and Market Perform to Hold; Sell, Underweight and Underperform to Sell. The recommendation breakdown counts the included houses at their latest rating.
Take this analysis with you
A branded consensus report on Genmab, ready to share or print.
Download PDF